Methods of Assessing Biological Activity of Recombinant Human Interleukin-7 and Stability Study of the Preparation on Its Basis
DOI:
https://doi.org/10.20535/1810-0546.2016.3.65102Keywords:
Interleukin-7, Human recombinant, Antiviral activity, Biological standardizationAbstract
Background. Interleukin-7 is one of the most important immune regulatory cytokines. Recombinant human interleukin-7 (rIL-7) in aqueous solution is subjected to chemical degradation mechanisms such as proteolysis, oxidation, disulfide exchange, oligomerisation etc. Such changes affect the shelf life of the preparation on the basis of rIL-7. Evaluation of the biological activity of rIL-7 can be carried out by assessing its antiviral activity.
Objective. Comparison of methods for inhibiting reproduction of the influenza virus, herpes simplex virus and hepatitis C virus with recombinant human interleukin-7 and research stability of the preparation on the basis of rIL-7.
Methods. We used immortalized cells: the kidneys of dogs, the bovine kidneys and kidneys of African green monkey Vero. The following viruses were used: hepatitis C virus surrogate (bovine viral diarrhea virus, BVDV), influenza virus (strain A/FM/1/47 (H1N1)), herpes simplex virus type 2 (HSV-2) (BH strain). To determine the antiviral activity of rIL-7 in vitro conditions using daily, immortalized cells. Cells were grown in RPMI-1640 medium.
Results. It was shown that rIL-7 in buffer stabilizing solutions and the culture medium after 1 week of storage was active at a dilution of 0.003 g/ml against BVDV. The study results of antiviral activity of rIL-7 drug in buffer solutions and culture medium against influenza virus A/FM/H1N1 can conclude that storage of the drug in buffer solution and in the intact state at 4 °C for one week has not affected its antiviral activity. It was shown that antiherpetic activity of preparations after 1 week of storage at 4 °C in buffer stabilizing solutions and intact state remained effective. The antiviral activity of drugs in a stabilizing solution has been persisted for 3 months at 4 °C, and in the intact state of rIL-7 lost its antiviral activity after 1 week against the herpes virus, and after 1 month regarding BVDV.
Conclusions. Methods for assessing the antiviral activity of rIL-7 towards BVDV, influenza virus, and HSV-2 were developed. It has been proven that the stabilizing buffer solutions proposed by us provide a high level of biological activity of rIL-7 preparations during storage at 4 °C for 3 months, which is a prerequisite for the development of liquid dosage forms of pharmaceutical preparations on their basis.References
T.J. Fry et al., “Interleukin-7: from bench to clinic”, Blood, vol. 99, no. 11, pp. 3892–3894, 2002.
T.N. Lutsenko and A.Yu. Galkin, “Substantiation of biotechnological approaches to get recombinant human interleukin-7”, Trudy Belarusskogo Gosudarsvennogo Tehnolgicheskogo Universita. Ser. Himija, Tehnologija Organicheskih Veshhestv i Biotehnologija, vol. 4, no. 177, pp. 188–197, 2015 (in Russian).
E. Bolotin et al., “Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count”, Bone Marrow Transplant., vol. 23, pp. 783–788, 1999.
S.A. Rosenberg et al., “IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells”, J. Immunother., vol. 29, no. 3, pp. 313–319, 2006.
Yu.I. Porva et al., “The study of antiviral activity of recombinant human interleukin-7 on various models of experimental hepatitis C virus infection // Naukovi Visti NTUU KPI, vol. 3, pp. 52–60, 2015 (in Ukrainian).
Biotechnological Bases of Creation of Tools for Serological Diagnosis of Infectious and Non-Infectious Diseases, V.P. Shyrobokov, Ed. Kyiv, Ukraine: NTUU KPI, 2015 (in Ukrainian).
T.M. Lutsenko et al., “Substantiation of parameters for standardization of drugs based on recombinant human interleukin-7”, Visnyk Natsionalnoho Universytetu “Lvivska Politekhnika”. Ser. Khimiia, Tekhnolohiia Rechovyn ta Yikh Zastosuvannia, vol. 812, pp. 175–183, 2015 (in Ukrainian).
Pui-Ho Ts. Yuen and D.F. Klein, “The preparations of alpha-interferon in the form of a stable aqueous solution”, Russian Federation Patent 2157236, IPC A61K38/21, A61K47/00, Oct. 10, 2000 (in Russian).
A.A. Gubaidullina et al., “Accelerated aging method for predicting the shelf life of the stabilized forms of alpha interferon”, Trudy Belarusskogo Gosudarsvennogo Universita. Ser. Fiziologicheskie, Biohimicheskie i Molekuljarnye Osnovy Funkcionirovanija Biosistem, vol. 4, no. 2, pp. 81–86, 2009 (in Russian).
D.K. Lvov, Virology Guide: Viruses and Viral Infections of Humans and Animals. Moscow, Russia: Med. Inform. Agentstvo, 2013 (in Russian).
A.A. Savchenko et al., “Modern methods of aspergillosis diagnosis and biotechnological approaches to creation of allergy/aspergillosis diagnostic preparations”, J. Health Sci., vol. 4, no. 1, pp. 363–374, 2014.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 NTUU KPI Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under CC BY 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
